Madopar® Quick

Levodopa / Benserazide, the active ingredient in Madopar® Quick, is a Levodopa/benserazide combination presented as an oral tablet for oral use. It is employed to increase central dopamine levels and is indicated for the symptomatic treatment of Parkinson’s disease in adult patients.

GNH USA supplies Madopar® Quick as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Our logistics network ensures timely delivery and temperature‑controlled handling where required.

Madopar® Quick, a Levodopa/benserazide combination, is used in the management of Parkinsonian disorders by restoring dopaminergic activity in the brain.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Drug‑induced Parkinsonian syndrome: alleviates motor deficits caused by dopamine‑blocking agents. - Early‑stage Parkinson’s disease: provides symptomatic relief to maintain functional independence.

Madopar® Quick may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: gastrointestinal upset occurring in many patients. - Orthostatic hypotension: drop in blood pressure upon standing. - Dyskinesia: involuntary movements, especially with long‑term use. - Dry mouth: reduced salivation. - Insomnia: difficulty initiating or maintaining sleep. - Vomiting: expulsion of stomach contents. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe hypotension: marked drop in blood pressure leading to fainting. - Cardiac arrhythmias: irregular heart rhythms. - Psychosis: hallucinations or delusional thoughts. - Allergic reactions: rash, pruritus, or anaphylaxis. - Severe depression: marked mood lowering and suicidal thoughts.

When prescribing Madopar® Quick, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust therapy as reduced clearance may increase plasma levels. - Hepatic dysfunction: monitor liver function because metabolism may be altered. - Cardiovascular disease: use caution due to risk of orthostatic hypotension and arrhythmias. - Psychiatric history: monitor for emergence of hallucinations or psychosis. - Concomitant MAO‑B inhibitors: avoid or separate dosing to prevent hypertensive crisis. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Madopar® Quick can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis. - Antipsychotics (e.g., haloperidol): block dopamine receptors and reduce therapeutic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism, diminishing benefit.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure lowering effect. - SSRIs and SNRIs: may increase risk of serotonin syndrome. - Iron or calcium supplements: reduce levodopa absorption if taken concurrently. - Diuretics: may potentiate orthostatic hypotension. - Carbonic anhydrase inhibitors: may enhance dopaminergic side effects.